PMID- 27409485
OWN - NLM
STAT- MEDLINE
DCOM- 20170615
LR  - 20220408
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 57
IP  - 9
DP  - 2016 Jul 1
TI  - Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF Treatment in 
      Age-Related Macular Degeneration: An Integrated Multimodal Imaging Analysis.
PG  - OCT288-98
LID - 10.1167/iovs.15-18753 [doi]
AB  - PURPOSE: To correlate presence of hyperreflective material (HRM) on 
      spectral-domain optical coherence tomography (SD-OCT) with color fundus 
      photography (CFP) in patients with different subtypes of neovascular age-related 
      macular degeneration (n-AMD). METHODS: Retrospective assessments were made at 
      baseline and months 1, 3, and 12 after initiation of treatment. At baseline, CFP 
      images were graded for the presence of blood, fibrin and lipid exudates, and 
      retinal angiograms for n-AMD subtype. At the four selected visits, SD-OCT scans 
      were graded for HRM type (well-defined or undefined) and location (subretinal, 
      intraretinal, and subretinal pigment epithelium [RPE]), integrity of RPE, 
      ellipsoid zone, and external limiting membrane (ELM). RESULTS: A total of 121 
      eyes with active n-AMD from 117 patients were included. At baseline, undefined 
      HRM was strongly associated with fibrin on CFP (chi2 = 39.87; P < 0.001). The 
      overall prevalence of HRM decreased from 85.9% at baseline to 52.9% by month 12. 
      From baseline to month 12, undefined HRM decreased (53.7% vs. 7.4%, respectively) 
      and well-defined HRM increased (32.2% vs. 45.5%, respectively). Sub-RPE HRM, 
      which was infrequent at baseline, increased up to 30.6% by month 12. At month 12, 
      eyes with no HRM had the best mean final best-corrected visual acuity (BCVA), and 
      those with undefined HRM the worst. Multivariate regression analysis showed that 
      ELM disruption at both baseline and month 12 was a negative predictive factor for 
      final BCVA (P = 0.001 and P < 0.001, respectively), whereas presence of 
      subretinal fluid at month 12 and number of treatments were positive predictors 
      for final BCVA (P = 0.007 and P = 0.041, respectively), but the covariates 
      describing HRM did not reach statistical significance in these models. 
      CONCLUSIONS: In eyes with n-AMD, location and morphology of HRM changed after 
      anti-VEGF treatment, and differences were observed in the various choroidal 
      neovascularization (CNV) subtypes. After anti-VEGF treatment, it was well-defined 
      HRM in the sub-RPE space that was observed mostly.
FAU - Casalino, Giuseppe
AU  - Casalino G
AD  - Ophthalmology Macular Service Belfast Health and Social Care Trust and Centre for 
      Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom 
      2Department of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute 
      University, Milan, It.
FAU - Bandello, Francesco
AU  - Bandello F
AD  - Department of Ophthalmology, Scientific Institute San Raffaele, Vita-Salute 
      University, Milan, Italy.
FAU - Chakravarthy, Usha
AU  - Chakravarthy U
AD  - Ophthalmology Macular Service Belfast Health and Social Care Trust and Centre for 
      Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Bevacizumab/*administration & dosage
MH  - Choroidal Neovascularization/*diagnosis/drug therapy/metabolism
MH  - Female
MH  - Fluorescein Angiography/*methods
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging/*methods
MH  - Retrospective Studies
MH  - Time Factors
MH  - Tomography, Optical Coherence/*methods
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity
MH  - Wet Macular Degeneration/*diagnosis/drug therapy/metabolism
EDAT- 2016/07/15 06:00
MHDA- 2017/06/16 06:00
CRDT- 2016/07/14 06:00
PHST- 2016/07/14 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/06/16 06:00 [medline]
AID - 2534118 [pii]
AID - 10.1167/iovs.15-18753 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT288-98. doi: 
      10.1167/iovs.15-18753.